John R Teerlink

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
    John R Teerlink
    School of Medicine, University of California San Francisco, San Francisco, CA, USA Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA Electronic address
    Lancet 388:2895-2903. 2016
  2. doi request reprint Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study
    John R Teerlink
    School of Medicine, University of California San Francisco, San Francisco, California Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, California Electronic address
    J Am Coll Cardiol 67:1444-55. 2016
  3. doi request reprint Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
    John R Teerlink
    University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121 1545, USA
    Lancet 381:29-39. 2013
  4. doi request reprint The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT
    John R Teerlink
    San Francisco Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, CA 94121 1545, USA
    Drug Saf 35:233-44. 2012
  5. pmc Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
    Trials 12:134. 2011
  6. pmc Relaxin: review of biology and potential role in treating heart failure
    Sam L Teichman
    Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp, San Mateo, CA 94402, USA
    Curr Heart Fail Rep 7:75-82. 2010
  7. pmc A novel approach to improve cardiac performance: cardiac myosin activators
    John R Teerlink
    University of California, San Francisco, USA
    Heart Fail Rev 14:289-98. 2009
  8. doi request reprint Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121 1545, USA
    Lancet 378:667-75. 2011
  9. ncbi request reprint Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    Am Heart J 150:46-53. 2005
  10. doi request reprint Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    Lancet 373:1429-39. 2009

Detail Information

Publications33

  1. doi request reprint Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial
    John R Teerlink
    School of Medicine, University of California San Francisco, San Francisco, CA, USA Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA Electronic address
    Lancet 388:2895-2903. 2016
    ..Impaired contractility is a feature of heart failure with reduced ejection fraction. We assessed the pharmacokinetics and effects on cardiac function and structure of the cardiac myosin activator, omecamtiv mecarbil...
  2. doi request reprint Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study
    John R Teerlink
    School of Medicine, University of California San Francisco, San Francisco, California Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, California Electronic address
    J Am Coll Cardiol 67:1444-55. 2016
    ..Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in healthy volunteers and in patients with chronic heart failure...
  3. doi request reprint Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
    John R Teerlink
    University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121 1545, USA
    Lancet 381:29-39. 2013
    ..The RELAX-AHF trial tested the hypothesis that serelaxin-treated patients would have greater dyspnoea relief compared with patients treated with standard care and placebo...
  4. doi request reprint The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT
    John R Teerlink
    San Francisco Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, CA 94121 1545, USA
    Drug Saf 35:233-44. 2012
    ..Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes...
  5. pmc Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication
    Roger J Lewis
    Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
    Trials 12:134. 2011
    ..We describe the design, oversight, and implementation of an adaptive, phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication...
  6. pmc Relaxin: review of biology and potential role in treating heart failure
    Sam L Teichman
    Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp, San Mateo, CA 94402, USA
    Curr Heart Fail Rep 7:75-82. 2010
    ..Ongoing, large-scale clinical testing will provide additional insights into the potential role of relaxin in the treatment of heart failure...
  7. pmc A novel approach to improve cardiac performance: cardiac myosin activators
    John R Teerlink
    University of California, San Francisco, USA
    Heart Fail Rev 14:289-98. 2009
    ..These studies suggest that cardiac myosin activators offer the promise of a safe and effective treatment for heart failure. A program of clinical studies are being planned to test whether CK-1827452 will fulfill that promise...
  8. doi request reprint Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121 1545, USA
    Lancet 378:667-75. 2011
    ..This study tested the hypothesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function in human beings...
  9. ncbi request reprint Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    Am Heart J 150:46-53. 2005
    ..Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated...
  10. doi request reprint Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    Lancet 373:1429-39. 2009
    ..We assessed the dose response of relaxin's effect on symptom relief, other clinical outcomes, and safety...
  11. ncbi request reprint The development of new medical treatments for acute decompensated heart failure
    John R Teerlink
    University of California, San Francisco, CA, USA
    Heart Fail Monit 2:129-37. 2002
    ..These three agents represent a new generation of therapeutics for this important medical problem and may provide the means not only to treat symptoms, but also to improve longer-term clinical outcomes...
  12. doi request reprint Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure
    Barry M Massie
    University of California at San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA 94121, USA
    N Engl J Med 363:1419-28. 2010
    ....
  13. pmc Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, USA
    Heart Fail Rev 14:243-53. 2009
    ....
  14. pmc Relaxin, a pleiotropic vasodilator for the treatment of heart failure
    Sam L Teichman
    Corthera Inc, San Mateo, CA, USA
    Heart Fail Rev 14:321-9. 2009
    ..This review will summarize both the biology of relaxin and the data supporting its potential efficacy in human heart failure...
  15. ncbi request reprint Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure
    Guillermo Torre-Amione
    Section of Cardiology, Methodist DeBakey Heart Center and Baylor College of Medicine, Texas Medical Center, One Baylor Plaza, Houston, TX 77030, USA
    J Am Coll Cardiol 42:140-7. 2003
    ..We sought to investigate the efficacy and safety of tezosentan, a dual endothelin receptor antagonist, in patients hospitalized for acute heart failure (HF)...
  16. ncbi request reprint Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction
    Marina R Bergman
    Department of Medicine, San Francisco Department of Veterans Affairs Medical Center University of California, San Francisco, California 94121, USA
    Am J Physiol Heart Circ Physiol 292:H1847-60. 2007
    ..5 +/- 1.5 vs. MMP 4.7 +/- 2.0; P = 0.016). Expression of active MMP-2 is sufficient to induce severe ventricular remodeling and systolic dysfunction in the absence of superimposed injury...
  17. pmc Determinants of hemodialysis-induced segmental wall motion abnormalities
    Ruth F Dubin
    Department of Medicine Nephrology, San Francisco VA Medical Center University of California, San Francisco, California, USA
    Hemodial Int 18:396-405. 2014
    ..Further studies are needed to determine the mechanism of this association and whether cardioprotective medications could ameliorate this adverse cardiac effect of hemodialysis...
  18. ncbi request reprint Overview of randomized clinical trials in acute heart failure syndromes
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, California 94121 1545, USA
    Am J Cardiol 96:59G-67G. 2005
    ....
  19. ncbi request reprint A rational approach for the treatment of acute heart failure: current strategies and future options
    Madan Sharma
    Section of Cardiology, San Francisco Veterans Affairs Medical Center and Department of Medicine, University of California San Francisco School of Medicine, USA
    Curr Opin Cardiol 19:254-63. 2004
    ..The purpose of this review is to discuss the current approach and the potential future strategies for treatment of patients with acute decompensated heart failure...
  20. doi request reprint What's new in the treatment of acute heart failure?
    Van N Selby
    Division of Cardiology, University of California, San Francisco, Box 0124, 505 Parnassus Ave, San Francisco, CA 94143 0124, USA
    Curr Cardiol Rep 15:393. 2013
    ..Novel drugs designed to maximize hemodynamic benefits while minimizing adverse effects are under investigation, with several agents showing promise in clinical studies. ..
  21. doi request reprint Role of tolvaptan in acute decompensated heart failure
    Jennifer E Ho
    University of California, San Francisco, CA, USA
    Expert Rev Cardiovasc Ther 6:601-8. 2008
    ....
  22. ncbi request reprint The role of endothelin in the pathogenesis of heart failure
    John R Teerlink
    Department of Cardiology, 111C, San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121 1545, USA
    Curr Cardiol Rep 4:206-12. 2002
    ..Clinical studies to date have not fulfilled this promise. Further analysis of these trials will hopefully provide insight into these disparate findings and guidance for future investigations...
  23. ncbi request reprint Endothelins: pathophysiology and treatment implications in chronic heart failure
    John R Teerlink
    Cardiology, 111C, San Francisco VAACE Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Curr Heart Fail Rep 2:191-7. 2005
    ..Further analysis of the data from these trials, as well as other ongoing studies, may provide insight into these disparate findings and guidance for future investigations...
  24. doi request reprint Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)
    Stephen J Greene
    From the Division of Cardiology, Duke University Medical Center, Durham, NC S J G, A F H, A P A, C M O, R J M Duke Clinical Research Institute, Durham, NC A F H, J L S, A P A, P J S, C M O, R J M Cardiology, University of Brescia, Italy M M Division of Cardiology, Stony Brook University, NY J B Canadian VIGOUR Center, University of Alberta, Edmonton, Canada J A E, P W A Cleveland Clinic, OH R C S Section of Cardiology, San Francisco Veterans Affairs Medical Center, School of Medicine, University of California San Francisco J R T and Department of Cardiology, University Medical Center Groningen, The Netherlands A A V
    Circ Heart Fail 9:. 2016
    ..Most international acute heart failure trials have failed to show benefit with respect to key end points. The impact of site enrollment and protocol execution on trial performance is unclear...
  25. doi request reprint Strategies to prevent postdischarge adverse events among hospitalized patients with heart failure
    Mitchell A Psotka
    Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Heart Fail Clin 9:303-20, vi. 2013
    ..Interventions that apply to multiple common medical comorbidities may be more likely to reduce overall adverse events. ..
  26. ncbi request reprint Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure
    John R Teerlink
    Heart Failure Clinic, San Francisco Veterans Affairs Medical Center and University of California, San Francisco, School of Medicine, San Francisco, Calif 94121 1545, USA
    Am Heart J 145:S26-33. 2003
  27. ncbi request reprint Nesiritide: a reappraisal of efficacy and safety
    Sanjiv J Shah
    University of California, Division of Cardiology, Department of Medicine, San Francisco, USA
    Expert Opin Pharmacother 8:361-9. 2007
    ..A large outcomes trial in patients with ADHF would help clarify the role of nesiritide...
  28. ncbi request reprint Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury
    Bo Qing Zhu
    Cardiology Section, VA Medical Center, Department of Medicine, University of California San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
    J Cardiovasc Pharmacol Ther 11:119-28. 2006
    ..Combination therapy further reduces infarct size. PQQ is superior to metoprolol in protecting mitochondria from ischemia/reperfusion oxidative damage...
  29. ncbi request reprint Reversal of left ventricular remodeling: role of the endothelin pathway
    John R Teerlink
    University of California and the Heart Failure Clinic, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Card Fail 8:S494-9. 2002
    ..This review discusses this role of the endothelin pathway in the development of left ventricular remodeling and the evidence that endothelin antagonists can reverse this deleterious process...
  30. ncbi request reprint Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?
    John R Teerlink
    School of Medicine, University of California, and the Section of Cardiology, Veterans Affairs Medical Center, San Francisco, CA 94121 1545, USA
    J Card Fail 8:124-7. 2002
  31. doi request reprint Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval
    Mitchell A Psotka
    School of Medicine, University of California San Francisco and Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, California
    JACC Heart Fail 4:791-804. 2016
    ..S. Food and Drug Administration (FDA) product label claim...
  32. pmc Association of segmental wall motion abnormalities occurring during hemodialysis with post-dialysis fatigue
    Ruth F Dubin
    Department of Medicine Nephrology, San Francisco VA Medical Center University of California, San Francisco, CA, USA
    Nephrol Dial Transplant 28:2580-5. 2013
    ..Post-dialysis fatigue (PDF) is a common, debilitating symptom that remains poorly understood. Cardiac wall motion abnormalities (WMAs) may worsen during dialysis, but it is unknown whether WMA are associated with PDF...
  33. ncbi request reprint The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?
    Mary Rose Fabi
    San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Curr Heart Fail Rep 2:59-64. 2005
    ..This review discusses the recent evidence for the addition of ARBs to standard therapy with ACE inhibitors and suggests how this evidence may be used to care for patients...